TrialSignal
Clinical trial intelligence report
Growth Hormone During Fasting. Signaltransduktion in Muscle and Adipose Tissue, Consequence of Growth Hormone Receptor Antagonist, Quantification of Intrahepatic Lipid Content Based on MR Scanning
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT00476879-Jul 28, 2026
NCT ID
NCT00476879
Status
COMPLETED
Phase
NA
Sponsor
University of Aarhus
Executive brief
Investment-Ready Snapshot
Growth Hormone During Fasting. Signaltransduktion in Muscle and Adipose Tissue, Consequence of Growth Hormone Receptor Antagonist, Quantification of Intrahepatic Lipid Content Based on MR Scanning is a NA clinical asset sponsored by University of Aarhus in Metabolism, Fatty Liver. SEO and diligence focus: Somatropin and pegvisomant, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00476879
Indication
Metabolism
Modality
small molecule
Target
Somatropin and pegvisomant
Intervention
Somatropin and pegvisomant
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.